Skip to Main Navigation Skip to the Content Skip to the Footer

TRIDENT EF-32: A Pivotal Randomized, Open –Label Study of Optune (TTFIELDS, 200KHZ) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

A Clinical Trial for Brain cancer in
  • Baton Rouge
.

To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and Temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and Temozolomide alone. In both arms, Optune® and maintenance Temozolomide are continued following radiation therapy.

Learn More